Goldman Sachs initiated coverage on Omega Therapeutics with a new price target
$OMGA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Goldman Sachs initiated coverage of Omega Therapeutics with a rating of Neutral and set a new price target of $22.00